Aprodex0.3%+0.1%

Ciprofloxacin and dexamethasone combination drops are used for bacterial infections accompanied by inflammation, in either the ear or the eye, depending on the specific product formulation. Otic (ear) and ophthalmic (eye) formulations of this combination are not interchangeable, and the generic name alone does not identify which route a given product is intended for.

• Otic formulations: acute otitis externa in pediatric, adult, and elderly patients caused by susceptible bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa; acute otitis media in pediatric patients (6 months and older) with tympanostomy tubes, caused by susceptible bacteria
• Ophthalmic formulations: bacterial conjunctivitis and other superficial bacterial eye infections with associated inflammation, where a specific product is licensed for ophthalmic use

A well-documented otic (ear) formulation contains ciprofloxacin hydrochloride 0.3% (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1% (equivalent to 1 mg dexamethasone) per mL. Ophthalmic formulations of this combination also exist in some markets, and their strength may differ. The generic name alone does not identify the specific strength or whether a given product is licensed for ear use, eye use, or both. Always confirm the intended route and exact strength on the specific product's own labeling before use.

Ciprofloxacin and dexamethasone is a combination antibiotic-steroid preparation that pairs a fluoroquinolone antibiotic (ciprofloxacin) with a corticosteroid (dexamethasone), used topically in the ear or eye. Ciprofloxacin treats the underlying bacterial infection, while dexamethasone reduces the inflammation, redness, and discomfort that often accompany it. This combination is for topical use only and is not intended for oral or systemic use.

Therapeutic Class: Otic/Ophthalmic Antibiotic-Corticosteroid Combination

Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic active against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa and Staphylococcus aureus, common causes of ear and eye infections. Dexamethasone provides anti-inflammatory activity in the affected tissue. Systemic absorption from topical otic or ophthalmic use is minimal; in pediatric patients receiving otic dosing through tympanostomy tubes, measurable plasma concentrations of both components were low, averaging a small fraction of levels seen with oral ciprofloxacin dosing.

Confirm whether the specific product being used is labeled for otic (ear) or ophthalmic (eye) use before administering, since these formulations and their application technique are not interchangeable.

If labeled for otic (ear) use

• Shake well immediately before use
• Warm the suspension by holding the bottle in the hand for 1-2 minutes to avoid dizziness from a cold suspension
• Lie with the affected ear facing upward, then instill the prescribed number of drops
• Gently pump the tragus (the small cartilage flap in front of the ear canal) 5 times to help the drops penetrate, if directed for use with tympanostomy tubes
• Remain in this position for about 1 minute after instillation

If labeled for ophthalmic (eye) use

• Wash hands before use
• Tilt the head back, gently pull down the lower eyelid to form a pocket, and instill the prescribed number of drops
• Avoid touching the dropper tip to the eye or any surface to prevent contamination

Systemic absorption from topical otic or ophthalmic use is generally minimal, so significant systemic drug interactions are uncommon with normal use. If other ear or eye medicines are used at the same time, they should be spaced apart, and any concerns should be discussed with a doctor or pharmacist.

Common side effects

• Ear or eye discomfort, itching, or irritation on instillation
• Ear canal debris or discharge
• Headache
• Redness at the application site

Serious side effects (with otic use)

• Signs of a hypersensitivity reaction: rash, swelling, difficulty breathing (systemic fluoroquinolone hypersensitivity and anaphylaxis have been reported, even with topical use)
• Tendon pain or inflammation (reported rarely with systemic fluoroquinolone exposure; exposure from otic use is substantially lower)

Serious side effects (with prolonged ophthalmic use)

• Raised intraocular pressure, cataract, or delayed wound healing associated with prolonged topical corticosteroid use
• Secondary ocular infection due to prolonged suppression of the local immune response

Pregnancy

There are no adequate, well-controlled studies of this combination in pregnant women. Because systemic absorption from topical otic or ophthalmic use is minimal, the product is generally expected to carry low risk of maternal or fetal toxicity, but it should be used during pregnancy only if a doctor determines it is appropriate.

Breastfeeding

It is not known whether ciprofloxacin and dexamethasone are present in human milk following topical otic or ophthalmic administration; because of minimal systemic absorption, breastfeeding is not expected to result in significant infant exposure to ciprofloxacin, but caution and medical guidance are advised, particularly given that systemically administered corticosteroids do appear in human milk.

• For otic use only in the ear, or ophthalmic use only in the eye, as labeled - never use one formulation for the other route.
• Avoid use in viral, fungal, or mycobacterial infections, as the corticosteroid component may worsen these conditions.
• For otic use: if otorrhea (ear discharge) persists after 7 days, or if 2 or more episodes occur within 6 months, further evaluation is warranted.
• For ophthalmic use: prolonged use of the corticosteroid component may raise intraocular pressure and increase the risk of cataract or secondary infection; monitor if used beyond about 7-10 days.
• Discontinue at the first sign of a rash or other hypersensitivity reaction.

Topical overdose is uncommon with normal use, but excessive or prolonged use may increase local irritation or, for ophthalmic use, the risk of corticosteroid-related eye effects. If the product is accidentally swallowed, or a large amount is applied, seek medical advice. Stop use and consult a doctor if irritation or symptoms worsen.

Store as directed on the product label, typically at controlled room temperature, protected from light and freezing, and tightly closed between uses. Do not use after the labeled expiry date, and discard any unused portion after the manufacturer's specified in-use period following opening.

• Pediatric patients: Otic use is established from 6 months of age for the approved indications; ophthalmic pediatric use should follow the specific product's own labeling.
• Elderly: Otic use is established in elderly patients for otitis externa; no specific dose adjustment generally required.

For otic indications, treatment is typically given for 7 days. For ophthalmic use, duration depends on the specific product and clinical response, and is generally limited given the risk of steroid-related eye effects with prolonged use; follow the prescribing doctor's instructions.

Drug Class: Fluoroquinolone antibiotic (ciprofloxacin) combined with a corticosteroid (dexamethasone), for topical otic or ophthalmic use

Ciprofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes bacteria need to replicate and repair their DNA, which kills susceptible bacteria. Dexamethasone works by suppressing local inflammatory mediators, reducing swelling, redness, and discomfort in the affected ear or eye. Together, the combination addresses both the infection and the associated inflammation.

The otic formulation of this combination is established for use in children 6 months of age and older for acute otitis externa and, in those with tympanostomy tubes, for acute otitis media, using the same 4-drop, twice-daily regimen as in adults. Use of an ophthalmic formulation in children should follow the specific product's own labeling and the prescribing doctor's guidance.